Lucrative niches: how drugs for rare diseases became lifeline for companies
- PMID: 16502531
Item in Clipboard
Lucrative niches: how drugs for rare diseases became lifeline for companies
Wall St J (East Ed).
.
No abstract available
Similar articles
-
[Orphan drugs--medications for patients with rare diseases].Ugeskr Laeger. 2006 Jun 5;168(23):2236-8. Ugeskr Laeger. 2006. PMID: 16768975 Danish.
-
Should off-label drug use be off-the-table?J Pediatr Endocrinol Metab. 2007 Feb;20(2):171-2. J Pediatr Endocrinol Metab. 2007. PMID: 17396432 No abstract available.
-
Support system: through charities, drug makers help people--and themselves.Wall St J (East Ed). 2005 Dec 1:A1, A10. Wall St J (East Ed). 2005. PMID: 16502554 No abstract available.
-
[Authorization and reimbursement of orphan drugs in an international comparison].Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16. Gesundheitswesen. 2011. PMID: 20848380 Review. German.
-
Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.Health Aff (Millwood). 2012 Nov;31(11):2528-35. doi: 10.1377/hlthaff.2012.0235. Health Aff (Millwood). 2012. PMID: 23129684 Review.
Cited by
-
Biosimilar growth hormone.Indian J Pediatr. 2012 Jan;79(1):92-8. doi: 10.1007/s12098-011-0610-y. Epub 2011 Nov 23. Indian J Pediatr. 2012. PMID: 22108957
-
The prevalence and cost of unapproved uses of top-selling orphan drugs.PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. Epub 2012 Feb 21. PLoS One. 2012. PMID: 22363762 Free PMC article.
-
On specialty pharmaceuticals: reflections of a second-year medical student.Biotechnol Healthc. 2006 Oct;3(5):41-4. Biotechnol Healthc. 2006. PMID: 23424384 Free PMC article.
-
Growth hormone and health policy.J Clin Endocrinol Metab. 2010 Jul;95(7):3149-53. doi: 10.1210/jc.2009-2688. Epub 2010 Apr 28. J Clin Endocrinol Metab. 2010. PMID: 20427500 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical